Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.030
+0.150 (5.21%)
At close: Jun 26, 2026, 4:00 PM EDT
3.060
+0.030 (1.00%)
After-hours: Jun 26, 2026, 6:49 PM EDT
Agenus Revenue
Agenus had revenue of $33.74M in the quarter ending March 31, 2026, with 40.18% growth. This brings the company's revenue in the last twelve months to $123.87M, up 24.46% year-over-year. In the year 2025, Agenus had annual revenue of $114.20M with 10.37% growth.
Revenue (ttm)
$123.87M
Revenue Growth
+24.46%
P/S Ratio
1.01
Revenue / Employee
$1,529,210
Employees
81
Market Cap
126.18M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 114.20M | 10.73M | 10.37% |
| Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
| Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
| Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
| Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
| Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
| Dec 31, 2019 | 150.05M | 113.26M | 307.92% |
| Dec 31, 2018 | 36.78M | -6.09M | -14.21% |
| Dec 31, 2017 | 42.88M | 20.30M | 89.95% |
| Dec 31, 2016 | 22.57M | -2.24M | -9.04% |
| Dec 31, 2015 | 24.82M | 17.84M | 255.67% |
| Dec 31, 2014 | 6.98M | 3.93M | 129.13% |
| Dec 31, 2013 | 3.05M | -12.92M | -80.92% |
| Dec 31, 2012 | 15.96M | 13.20M | 479.17% |
| Dec 31, 2011 | 2.76M | -603.84K | -17.97% |
| Dec 31, 2010 | 3.36M | 25.17K | 0.75% |
| Dec 31, 2009 | 3.33M | 683.36K | 25.78% |
| Dec 31, 2008 | 2.65M | -2.90M | -52.25% |
| Dec 31, 2007 | 5.55M | 4.86M | 702.20% |
| Dec 31, 2006 | 692.14K | 62.16K | 9.87% |
| Dec 31, 2005 | 629.98K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Spero Therapeutics | 61.19M |
| Coya Therapeutics | 7.94M |
| NRx Pharmaceuticals | 2.29M |
| NeOnc Technologies Holdings | 39.99K |
| Genelux | 8.00K |
| Fractyl Health | 3.00K |
AGEN News
- 1 day ago - Agenus announces three-year survival data from Phase 1b BOT+BAL study - TheFly
- 1 day ago - Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026 - Business Wire
- 10 days ago - Agenus Transcript: AGM 2026 - Transcripts
- 24 days ago - Agenus Announces Virtual 2026 Annual Shareholders Meeting - Business Wire
- 5 weeks ago - Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC - Business Wire
- 5 weeks ago - Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 - Business Wire
- 6 weeks ago - Agenus announces publication of Phase 1b BOT+BAL data - TheFly
- 6 weeks ago - Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer - Business Wire